Acute neuromodulatory effects of 1 Hz rTMS on the central autonomic network in depression: A concurrent TMS-fMRI study.

J Affect DisordJul 16, 2026 (epub)
Clinical ResearchPsychiatry

Elizabeth C Gregory, Bazyl Carroll, Jaeyoon Kim et al.

✦ AI-curated · Sources linked

In 30 seconds

This clinical trial investigated the acute effects of 1 Hz repetitive transcranial magnetic stimulation (rTMS) on the central autonomic network (CAN) in patients with major depressive disorder (MDD). Using concurrent rTMS-fMRI, the study found that rTMS increased the temporal correlation between heart rate variability (HRV) and BOLD signal in the right posterior insula, while HRV decreased during the procedure.

Key findings

  • TMS-fMRI increased temporal correlation between BOLD signal in the right posterior insula and HRV.
  • HRV decreased during TMS-fMRI.
  • Weak correlation trends were observed between increased CAN activity and treatment outcomes.

Why it matters

Understanding the effects of rTMS on the central autonomic network may enhance treatment strategies for major depressive disorder, particularly regarding autonomic dysregulation. Insights into HRV changes could inform future therapeutic approaches.

Source

PubMed · PMID 42462929

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.